Quanterix Corporation (QTRX)
| Market Cap | 258.22M |
| Revenue (ttm) | 135.69M |
| Net Income (ttm) | -47.87M |
| Shares Out | 38.83M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,331,970 |
| Open | 6.81 |
| Previous Close | 6.57 |
| Day's Range | 6.49 - 6.81 |
| 52-Week Range | 4.05 - 16.74 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 15.60 (+134.59%) |
| Earnings Date | Aug 7, 2025 |
About QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of ... [Read more]
Financial Performance
In 2024, Quanterix's revenue was $137.42 million, an increase of 12.30% compared to the previous year's $122.37 million. Losses were -$38.53 million, 35.9% more than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for QTRX stock is "Buy." The 12-month stock price forecast is $15.6, which is an increase of 134.59% from the latest price.
News
Quanterix Expands Reach with IVD and Large Reference Labs
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoas...
Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders
RINCON, Puerto Rico , June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company...
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe...
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company"...
Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Joshua Young - Head, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Confer...
Quanterix Releases Financial Results for the First Quarter of 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Bioscience...
Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...
Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QT...
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences ...
Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QT...
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (“Quanterix”...
Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: ...
Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried...
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (Nasdaq: QTR...
Quanterix Corporation (QTRX) Q4 2024 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Joshua Young - Head of IR Masoud Toloue - President and CEO Vandana Sriram - CFO Co...
Quanterix Releases Financial Results for the Fourth Quarter of 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of 7.47% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Kent L...
Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...
Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) a holder of 7.25% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today iss...
Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 6.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), announced...
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiter...
The Schall Law Firm Invites Shareholders With Losses In Quanterix Corporation To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Co...
Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer's Disease
Neurogen Biomarking's Brain Health Care Ecosystem Gives Patients Easier Access to Clinically Validated Blood Biomarker Technology Neurogen Biomarking's Brain Health Care Ecosystem Gives Patients Easie...
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today hig...